XOMA

XOMA Royalty Corp

40.17

Jul 13 • 03:59PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: LGND BMRN INCY RYTM VRTX FNV OR RGLD WPM NBIX

| Held by: VTI VXF VTWO VHT VTWG VTWV VTHR

Index	-
Market Cap	710.21M
Enterprise Value	760.05M
Income	19.95M
Sales	48.55M
Book/sh	7.79
Cash/sh	5.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	14
IPO	Jun 06, 1986

P/E	25.57
Forward P/E	-
PEG	-
P/S	14.63
P/B	5.15
P/C	7.48
P/FCF	107.12
EV/EBITDA	91.68
EV/Sales	15.65
Quick Ratio	3.59
Current Ratio	3.59
Debt/Eq	1.10
LT Debt/Eq	0.96
Option/Short	Yes / No

EPS (ttm)	1.57
EPS next Y	-0.05
EPS next Q	0.18
EPS this Y	-46.22%
EPS next Y	-106.10%
EPS next 5Y	-
EPS past 3/5Y	- 13.20%
Sales past 3/5Y	105.30% 12.16%
EPS Y/Y TTM	249.73%
Sales Y/Y TTM	13.16%
EPS Q/Q	207.83%
Sales Q/Q	-22.59%
Earnings	Apr 30
EPS/Sales Surpr.	30.51% 0.26%

Insider Own	2.33%
Insider Trans	0.00%
Inst Own	42.01%
Inst Trans	-
ROA	10.55%
ROE	25.88%
ROIC	11.55%
Gross Margin	93.16%
Oper. Margin	10.25%
Profit Margin	41.08%
SMA20	-5.68%
SMA50	-4.49%
SMA200	19.20%
Trades

Shs Outstand	17.68M
Shs Float	17.27M
Short Float	5.30%
Short Ratio	2.73
Short Interest	0.91M
52W High	45.22 -11.17%
52W Low	22.29 80.22%
Volatility	3.85% 1.79%
ATR (14)	0.91
RSI (14)	34.34
Beta	0.88
Rel Volume	0.00
Avg Volume	335.20K
Volume	0

Perf Week	-9.16%
Perf Month	-3.85%
Perf Quarter	1.41%
Perf Half Y	36.82%
Perf YTD	51.07%
Perf Year	48.01%
Perf 3Y	135.74%
Perf 5Y	22.32%
Perf 10Y	292.29%
Recom	3.00
Target Price	39.00
Prev Close	40.17
Price	40.17
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	The Benchmark Company	Buy	$35
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6

Show Previous Ratings

Jul-14-26 09:00AM	XOMA Royalty Announces Closing of Its Acquisition by Ligand (GlobeNewswire)
Jun-12-26 04:05PM	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date (GlobeNewswire)
11:47AM	Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-14-26 05:25PM	Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-08-26 05:57PM	Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? (PR Newswire)
02:55PM	Loading…
May-04-26 02:55PM	Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-27-26 11:24AM	Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? (PR Newswire) +10.74%
10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Mar-18-26 04:30PM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +5.16%
06:00AM	XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Mar-12-26 06:30AM	XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 (GlobeNewswire)
Feb-18-26 04:30PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-09-26 09:53AM	XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. (GlobeNewswire)
07:30AM	Loading…
Jan-12-26 07:30AM	XOMA Royalty Announces CFO Transition (GlobeNewswire) -10.25%
Jan-05-26 08:48AM	Implied Volatility Surging for XOMA Royalty Stock Options (Zacks)
Dec-30-25 07:30AM	XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab (GlobeNewswire)
Dec-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-11-25 06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) -22.76%
Dec-05-25 09:00AM	XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc (GlobeNewswire)
Nov-21-25 07:45AM	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Nov-12-25 08:45AM	XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-28-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates (Zacks)
Oct-20-25 09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
11:45AM	Loading…
Oct-17-25 11:45AM	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement (GlobeNewswire)
Oct-02-25 04:43PM	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Sep-24-25 06:00AM	ESSA Pharma Inc. Amends Agreement with XenoTherapeutics (PR Newswire)
Sep-23-25 02:00AM	Why Xoma, a drug royalty firm, is hunting biotech zombies (BioPharma Dive)
Sep-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-19-25 09:55AM	Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect? (Zacks)
Sep-17-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. (GlobeNewswire)
Sep-03-25 09:55AM	Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know (Zacks)
07:30AM	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-01-25 09:55AM	Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
08:49AM	Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share (GlobeNewswire)
Aug-18-25 09:55AM	How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% (Zacks)
Aug-13-25 04:55PM	LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +8.54%
08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:51AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-11-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics (GlobeNewswire)
Aug-07-25 05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-06-25 09:10AM	Novavax (NVAX) Q2 Earnings and Revenues Top Estimates (Zacks) -7.10%
Aug-04-25 08:15AM	Xoma strikes deals to buy struggling biotechs HilleVax, Lava (BioPharma Dive) +10.01%
07:30AM	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right (GlobeNewswire)
07:00AM	HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
Jul-14-25 08:00AM	ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction (PR Newswire)
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jun-27-25 07:30AM	Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jun-24-25 10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks) +5.23%
Jun-18-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
May-27-25 08:01AM	XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million (GlobeNewswire)
May-13-25 08:50AM	XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates (Zacks) +10.89%
07:48AM	XOMA Royalty: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements (GlobeNewswire)
May-07-25 07:30AM	XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire) +6.25%
Apr-22-25 04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-14-25 07:30AM	XOMA Royalty Completes Sale of Kinnate Pipeline Assets (GlobeNewswire)
Apr-09-25 09:45AM	XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey) +7.62%
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-02-25 07:30AM	XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-20-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-17-25 04:30PM	XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements (GlobeNewswire)
Feb-24-25 04:05PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-04-25 07:30AM	XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-19-24 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-02-24 07:30AM	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio (GlobeNewswire)
Nov-11-24 12:00PM	What Makes XOMA Royalty (XOMA) a New Buy Stock (Zacks)
Nov-07-24 09:00AM	XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.96%
07:52AM	XOMA Royalty: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Oct-22-24 08:00AM	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience (GlobeNewswire)
08:00AM	Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash (Business Wire)
Sep-23-24 06:30AM	Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
05:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-04-24 07:30AM	XOMA Royalty to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 08:45AM	XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:39AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Jul-18-24 04:08AM	Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-21-24 07:54AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock? (Zacks) -5.23%
Jun-20-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +15.64%
Jun-12-24 07:30AM	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher (GlobeNewswire)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Chief Investment OfficerMr. Bradley Sitko

Chief Financial OfficerMr. Jeffrey Trigilio

Head of Investor RelationsJuliane Snowden

Chief Legal Officer & Corporate SecretaryMs. Maricel Perea Montano

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Trigilio Jeffrey	Chief Financial Officer	Apr 20 '26	Option Exercise	0.00	11,538	0	103,906	Apr 22 04:30 PM
Montano Maricel Perea	Chief Legal Officer	Apr 20 '26	Option Exercise	0.00	3,370	0	41,793	Apr 22 04:30 PM
Hughes Owen	Chief Executive Officer	Apr 20 '26	Option Exercise	0.00	10,568	0	191,264	Apr 22 04:30 PM
Sitko Bradley	Chief Investment Officer	Apr 20 '26	Option Exercise	0.00	3,737	0	82,961	Apr 22 04:30 PM
Trigilio Jeffrey	Chief Financial Officer	Apr 13 '26	Option Exercise	0.00	4,000	0	94,000	Apr 15 06:13 PM
LIMBER JOSEPH M	Director	Mar 27 '26	Option Exercise	11.20	3,026	33,891	9,234	Mar 31 04:30 PM
WYSZOMIERSKI JACK L	Director	Mar 24 '26	Option Exercise	11.20	3,026	33,891	21,530	Mar 26 04:30 PM
Hughes Owen	Chief Executive Officer	Dec 04 '25	Buy	25.05	100,000	2,505,000	102,000	Dec 08 04:30 PM
Sitko Bradley	Chief Investment Officer	Sep 19 '25	Option Exercise	0.00	6,712	0	19,822	Sep 23 05:32 PM
Hughes Owen	Chief Executive Officer	Sep 19 '25	Option Exercise	0.00	35,567	0	98,268	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 19 '25	Option Exercise	0.00	11,846	0	34,409	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 22 '25	Sale	35.99	4,330	155,820	30,079	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 19 '25	Option Exercise	0.00	3,033	0	12,134	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 10 '25	Option Exercise	0.00	9,101	0	9,101	Sep 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XOMA

XOMA Royalty Corp

Upgrade your Finviz experience